SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

Home・Akcijų sąrašas・RHOEN-KLINIKUM AG

RHOEN-KLINIKUM AG

Uždarymo kaina

11.1 -1.77

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

11.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-6.9M 7.1M
Pardavimai	-9.8M 415M
P/E Sektoriaus vid.	20 40.048
Pelnas, tenkantis vienai akcijai	0.107
Dividendų pajamingumas	0.84
Pelno marža	1.72
Darbuotojai	18,819
EBITDA	-14M 25M

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.84% 2.45%
Kitas uždarbis	2025-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-120M 810M
Ankstesnė atidarymo kaina	12.87
Ankstesnė uždarymo kaina	11.1

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

N/A / 15.2 Palaikymas ir pasipriešinimas

RHOEN-KLINIKUM AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis

Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

RHOEN-KLINIKUM AG Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių RHOEN-KLINIKUM AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 15.2Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę RHOEN-KLINIKUM AG

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. It also operates acute hospitals, medical care centers, and rehabilitation hospitals. The company was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.